Want to see DE:FME full AI Analyst Report?
FME Stock Chart & Stats
€38.69
-€0.05(-0.11%)
At close: 4:00 PM EST
€38.69
-€0.05(-0.11%)
Day’s Range― - ―
52-Week Range€34.57 - €49.10
Previous CloseN/A
Volume12.09K
Average Volume (3M)529.60K
Market Cap
€10.86B
Enterprise Value€20.90B
Total Cash (Recent Filing)€1.24B
Total Debt (Recent Filing)€11.03B
Price to Earnings (P/E)12.5
Beta0.55
Next Earnings
Aug 04, 2026EPS Estimate
1.04Next Dividend Ex-DateN/A
Dividend Yield3.54%
Share Statistics
EPS (TTM)3.28
Shares Outstanding268,564,640
10 Day Avg. Volume492,004
30 Day Avg. Volume529,597
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.89
Price to Sales (P/S)0.60
P/FCF Ratio6.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.24Price Target Upside-1.16% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering11
EPS Forecast (FY)4.01
Revenue Forecast (FY)€19.30B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthSustained, sizable operating and free cash flow provides durable internal funding for capex, dividends, and debt reduction. Strong cash conversion (FCF ~65% of net income) improves financial flexibility versus peers and supports strategic investments and resilience through reimbursement cycles.
Integrated Care + Products ModelA vertically integrated model links clinic volumes to recurring consumable and service sales, creating repeatable demand and cross-selling. The installed equipment base and clinic footprint support predictable consumable revenue and aftermarket services, strengthening long-term commercial durability.
Improving LeverageMeaningful reduction in leverage de-risks the balance sheet and lowers refinancing and interest exposure. Improved leverage enhances capacity for strategic M&A, investment in clinics and manufacturing, and provides a stronger foundation to navigate reimbursement and macro headwinds.
Bears Say
Stagnant Revenue TrendA flat-to-slightly-declining top line limits growth optionality and increases reliance on cost cuts or mix shifts to lift earnings. Without durable patient volume growth or improved reimbursement, long-term EPS gains must come from efficiency or pricing power, which can be constrained in healthcare markets.
Moderate, Volatile MarginsRelatively modest and historically volatile margins constrain the company's buffer against cost inflation or reimbursement cuts. Low margins reduce ability to absorb adverse regulatory or supply shocks and make sustained earnings expansion sensitive to operational execution and pricing leverage.
Payor & Regulatory ExposureRevenue and profitability are structurally tied to government and insurer reimbursement rules and regulatory regimes. Changes in payor policy, reimbursement rates, or clinic funding generate lasting revenue pressure and require strategic adaptation, creating persistent external policy risk.
FME FAQ
What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
Fresenius Medical Care AG & Co. KGaA lowest stock price was €34.57 and its highest was €49.10 in the past 12 months.
What is Fresenius Medical Care AG & Co. KGaA’s market cap?
Fresenius Medical Care AG & Co. KGaA’s market cap is €10.86B.
When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Aug 04, 2026 which is in 36 days.
How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
Fresenius Medical Care AG & Co. KGaA released its earnings results on May 05, 2026. The company reported €0.91 earnings per share for the quarter, missing the consensus estimate of €1.012 by -€0.102.
Is Fresenius Medical Care AG & Co. KGaA overvalued?
According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Overvalued.
Does Fresenius Medical Care AG & Co. KGaA pay dividends?
Fresenius Medical Care AG & Co. KGaA pays a Annually dividend of €1.49 which represents an annual dividend yield of 3.54%. See more information on Fresenius Medical Care AG & Co. KGaA dividends here
What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 1.04.
How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
Fresenius Medical Care AG & Co. KGaA has 268,564,640 shares outstanding.
What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
Fresenius Medical Care AG & Co. KGaA reported an EPS of €0.91 in its last earnings report, missing expectations of €1.012. Following the earnings report the stock price went down -10.678%.
Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
Currently, no hedge funds are holding shares in DE:FME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care AG & Co. KGaA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€38.24 (-1.16% Downside)
€38.24 (-1.16% Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.79%
12-Months-Change
Fundamentals
Return on Equity
7.16%
Trailing 12-Months
Asset Growth
-3.87%
Trailing 12-Months
Company Description
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
FME Stock 12 Month Forecast
Average Price Target
€38.24
▼(-1.16% Downside)
Technical Analysis
Options Prices
Currently, No data available
---






